Navigation Links
Chiltern Announces New Legal Entity In Taiwan
Date:4/23/2012

LONDON, April 23, 2012 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that the company has established a new legal entity in Taiwan.

Dr. Umakanta Sahoo, Chiltern Executive Director, Asia Pacific and Managing Director, India, commented, "Chiltern has already established a strong presence in this region with its offices in India, Singapore and Australia and hence forming a legal entity in other important countries in the region is a natural progression to enhance our global reach." Dr. Sahoo, who will be leading the effort in Taiwan, continued, "With the regional collaboration between Asian countries for mutual acceptance of Asian data, Japan, USA and European clients have shown increased interest in Taiwan to perform global clinical trials due to supportive regulatory environment, excellent hospital infrastructure and healthcare system."

Aize Smink, Chiltern Sr. Executive VP, Global Clinical Development, stated, "We are very pleased to be able to start offering clinical research services in Taiwan as part of our global clinical development capabilities. Taiwan has an excellent medical infrastructure, high quality investigators and research staff to serve our global client base."

Company profileAbout Chiltern:Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs nearly 1,300 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com. For More Information Contact:Natalie Chong

Susan OjanenMarketing Director

Marketing ExecutiveChiltern International Ltd.

Chiltern International Inc.171 Bath Road

1241 Volunteer ParkwaySlough

Suite 950Berkshire SL1 4AA

Bristol, TN 37620UNITED KINGDOM

USATel:  +44 (0) 1753 512 000

Tel:  +1 (423) 968 9533Fax: +44 (0) 1753 511 116

Fax: +1 (423) 968 3567Email: natalie.chong@chiltern.com 

Email: susan.ojanen@chiltern.com


'/>"/>

SOURCE Chiltern
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chiltern Early Phase: Fully Integrated and Business Ready
2. Chiltern Is a Nominee on the SCRIP CRO of the Year Award Shortlist
3. Chiltern Announces Additional Investment in Endpoint
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
5. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Anesiva Announces Second Quarter 2008 Financial Results and Update
8. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
Breaking Biology News(10 mins):